ERNA vs. MRSN, BTAI, ALVR, JSPR, EGRX, XFOR, ATHE, OKUR, ELUT, and SONN
Should you be buying Ernexa Therapeutics stock or one of its competitors? The main competitors of Ernexa Therapeutics include Mersana Therapeutics (MRSN), BioXcel Therapeutics (BTAI), AlloVir (ALVR), Jasper Therapeutics (JSPR), Eagle Pharmaceuticals (EGRX), X4 Pharmaceuticals (XFOR), Alterity Therapeutics (ATHE), OnKure Therapeutics (OKUR), Elutia (ELUT), and Sonnet BioTherapeutics (SONN). These companies are all part of the "pharmaceutical products" industry.
Ernexa Therapeutics vs. Its Competitors
Mersana Therapeutics (NASDAQ:MRSN) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.
Ernexa Therapeutics has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -212.94%.
93.9% of Mersana Therapeutics shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 13.0% of Mersana Therapeutics shares are held by insiders. Comparatively, 1.5% of Ernexa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Mersana Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Ernexa Therapeutics has a beta of 5.62, indicating that its stock price is 462% more volatile than the S&P 500.
In the previous week, Mersana Therapeutics had 1 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 2 mentions for Mersana Therapeutics and 1 mentions for Ernexa Therapeutics. Mersana Therapeutics' average media sentiment score of 0.63 beat Ernexa Therapeutics' score of 0.47 indicating that Mersana Therapeutics is being referred to more favorably in the media.
Mersana Therapeutics currently has a consensus price target of $56.60, suggesting a potential upside of 433.96%. Given Mersana Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Mersana Therapeutics is more favorable than Ernexa Therapeutics.
Ernexa Therapeutics has lower revenue, but higher earnings than Mersana Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Mersana Therapeutics beats Ernexa Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Ernexa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ERNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ernexa Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ERNA) was last updated on 10/16/2025 by MarketBeat.com Staff
